Generic Rectiv

The exclusivity rights for Rectiv (nitroglycerin anal ointment) currently expire in June 2014. That is the earliest possible date that a generic version could become available. However, other circumstances, such as lawsuits or additional exclusivity rights, could come up to extend the exclusivity period beyond that time.

Can I Buy Generic Rectiv?

Rectiv™ (nitroglycerin anal ointment) is a prescription medication used for treating anal fissures. Specifically, it is usually used twice a day, for up to three weeks, to help relieve pain associated with anal fissures. This product is the first (and currently only) nitroglycerin ointment approved for this use.
 
Rectiv is made by PHARBIL Waltrop GmbH for ProStrakan, Inc. It is not available in generic form.
 

When Will a Generic Version Be Available?

The exclusivity rights for Rectiv (which are similar to patents) are currently set to expire in June 2014. This is the earliest predictable date that a generic version could become available.
 
However, other circumstances could come up to extend or shorten the exclusivity period. This could include such things as lawsuits or additional exclusivity rights. Once the exclusivity rights expire, there may be several companies that manufacture a generic Rectiv drug.
 

Is Nitro-Bid Ointment a Generic Rectiv?

No -- Rectiv comes in a 0.4% ointment. Nitro-Bid comes in a 2% ointment, much too strong for treating anal fissures. In addition, Nitro-Bid is officially approved to treat chest pain (angina).
 
In the past, pharmacists would compound (mix up) a weaker nitroglycerin ointment for this purpose,often by diluting Nitro-Bid. However, these compounded products cannot be considered generic versions of Rectiv. In fact, it is not legal for pharmacists to compound a medication in the same formulation and strength as a commercially available product. However, it is still legal for pharmacists to make strengths other than the 0.4% ointment.
 
Written by/reviewed by: Kristi Monson, PharmD
Last reviewed by: Kristi Monson, PharmD
Other Articles in This eMedTV Presentation